All Brands Owned by Vertex Pharmaceuticals Incorporated

What does Vertex Pharmaceuticals own?
Vertex owns seven marketed medicines: CF therapies Kalydeco, Orkambi, Symdeko, Trikafta/Kaftrio, and Alyftrek, plus Casgevy (co-owned profit share with CRISPR Therapeutics) and Journavx. Its pipeline includes povetacicept, zimislecel, and inaxaplin. It absorbed Semma, ViaCyte, and Alpine Immune Sciences rather than holding them as separate companies.

Is Vertex publicly traded?
Yes. It trades on NASDAQ under ticker VRTX and is a member of the S&P 500 and NASDAQ-100. Shares have been public since a 1991 IPO.

When was Vertex founded?
Vertex was founded in 1989 in Cambridge, Massachusetts. It moved its headquarters to Boston's Seaport District in 2014.

Who founded Vertex?
Joshua Boger, a former senior scientist at Merck, founded the company with venture capitalist Kevin Kinsella to pursue rational drug design. Reshma Kewalramani is the current president and CEO.

What is Vertex's market position?
Vertex holds an effective monopoly in cystic fibrosis modulators, with medicines used by about 75% of the addressable patient population across 60-plus reimbursed countries. It is among the most valuable biotechnology companies by market capitalization.

Does Vertex own Casgevy?
Vertex co-developed Casgevy with CRISPR Therapeutics and leads commercialization under a profit-sharing agreement, taking 60% of economics. It is not the sole owner of the product.